Company Overview and News
SAN FRANCISCO/HONG KONG (Reuters) - For three whirlwind days in June, U.S. scientist Zhi Hong went shopping at the Boston Bio Conference to find drugs to fill the pipeline of his two-week-old drug company.
BABA GSK GSK
AstraZeneca (AZN - Free Report) announced positive long-term safety and efficacy data on Fasenra (benralizumab) from the phase III BORA extension study, evaluating the drug as an add-on maintenance treatment for severe eosinophilic asthma patients who were previously treated in pivotal SIROCCO or CALIMA studies.
AZN AMGN UNP TEVJF AZN TEVA GSK TEVVF GSK
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
Results from an exploratory Phase 3 trial of Alnylam Pharmaceuticals’s (ALNY) Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published in the journal Circulation.
AGN KPTI THERF GSK PFE GSK BCDA ALNY
GlaxoSmithKline (GSK - Free Report) announced that its HIV-focused company, ViiV Healthcare submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for a single-tablet, two-drug regimen of dolutegravir (Tivicay) and lamivudine (Epivir) for the treatment of HIV-1 infection.
GSK GSK PFE
But for PMD, Big pharma drug makers and biotech continued to top the healthcare sector by yield and broker targets. WallStars are distinguished by positive broker target price upsides.
GRFS ACET GILD AZN MCK CVS GSK SNY AZN AGN PMD NVS GSK ABBV CAH PFE ABBV
Lupin on Wednesday said it has received nod from the US Food and Drug Administration to market its Atovaquone oral suspension in the strength of 750 mg/5 mL. The product is a generic version of GlaxoSmithKline LLC’s Mepron oral suspension in the same strength, it added.
Drug firm Lupin Wednesday said it has received nod from the US health regulator to market its Atovaquone oral suspension used for prevention and treatment of a type of pneumonia.
GlaxoSmithKline plc (GSK - Free Report) announced that the FDA has issued a complete response letter (CRL) to its supplemental biologics license application (sBLA) for label expansion of its asthma drug, Nucala for a new indication — eosinophilic chronic obstructive pulmonary disease (COPD).
HIK NVS GSK GSK
Mumbai: The biggest mergers and acquisitions (M&A) boom in Indian history has investment bankers preparing for even more deal-making to come. Transactions involving Indian companies have reached $104.5 billion in 2018, trouncing the previous annual record with almost four months left in the year, according to data compiled by Bloomberg. The tally may surpass $100 billion again in 2019, said Sanjeev Krishan, a Gurgaon-based partner at PwC India who focuses on private equity and deals.
523405 NMR BHUSANSTL 500470 8604 NRSCF GSK MS 500055 JMFINANCIL GSK BRK.A BABA TTST N33 TATASTEEL TATLY 0700 KHC
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to LSE:GSK / GLAXOSMITHKLINE on message board site Silicon Investor.